The summit was held July 15 at Carnegie Mellon University and featured top executives in energy and AI, global investors, among others.

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much ...